About this trial

Despite many advances in our understanding of the natural history and progression of chronic kidney disease (CKD) and cardio vascular disease (CVD) in the parent CRIC study over the past 15 years, important questions about key risk factors for these diseases remain unanswered in the AI population. To address this burden of CKD in AI communities Investigators formed a consortium of investigators with extensive experience in conducting research of chronic diseases including diabetes, cardiovascular and kidney disease in AIs of Southwestern US. The proposed CRIC ancillary cohort study of 500 AIs (AI-CRIC) will rapidly improve our understanding of both potential risk factors for CKD progression, as well as the scope of this disease among AIs. This study leverages the current CRIC study and incorporates the planned activities of the next phase of the study - "CRIC 2018" - by implementing contemporary CRIC protocols for kidney and cardiovascular measurement and outcomes.

Eligibility criteria

Qualifiers

Glomerular Filtration Rate (GFR): eGFR of =>61<80 and microalbuminuria > 30 or eGRF of =<60 (no microalbuminuria required).

Disqualifiers

Unable or unwilling to provide informed consent

life expectancy <3 years;

institutionalized subjects;

End stage renal disease or renal transplant;

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

3
NIDDK-Phoenix Epidemiology and Clinical Research85016, PhoenixArizona, United States
First Nations Community Health Source87108, AlbuquerqueNew Mexico, United States
Zuni Health Initiative Center87327, Black RockNew Mexico, United States

Sponsors and collaborators

University of New Mexico

Lead sponsor